TrialRheumatology (Oxford, England)2022

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.

Elizabeth Price et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.